P3 Health Partners Inc (PIII)

Q: What's priced into P3 Health Partners Inc (PIII) stock?

The evidence does not provide a peer valuation comparison or a clear account of what expectations the market already assumes. Its valuation measure fell from 70.0 to 55.6, a 14.4-point decline, but that alone does not establish whether the shares are cheap, fair, or expensive.

Q: What does the P3 Health Partners Inc (PIII) outlook hinge on?

The thesis depends on continued progress toward management’s 2026 revenue and EBITDA priorities, while resolving the Nasdaq compliance issue. A guidance reversal after a recent raise would damage credibility, and weakening employment could increase pressure on cyclical Healthcare names; continued earnings strength from HCA, THC, and EHC would support the sector backdrop.

NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-10-23

$4.14-5.05%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge P3 Health Partners Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	393.55M
EPS	—	-5.62
FY 2026 · Annual
Revenue	$1.5B–$1.6B	1.55B
EPS	—	-7.27
EBITDA	$80M–$110Mnon-GAAP	—
FY 2027 · Annual
Revenue	—	1.7B
EPS	—	-10.165

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Raise adjusted EBITDA to $40M in 2026	Adjusted EBITDA is targeted at $40M for the year.	Intact	Adjusted EBITDA remains below $20 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA improved from a loss of $17.1M in 2025-Q2 to a gain of $54.4M in 2026-Q2. Management raised full-year 2026 adjusted EBITDA outlook to a midpoint of $40M after Q1 and Q2 results. The trajectory is delivering against this priority. Delivery assessment Oct 24, 2026
Reduce net losses toward break-even	A supporting condition in P3 Health Partners Inc's published investment case. The stated target is Net loss less negative than -$95 million in FY25, improving in FY26.	Improving	Net loss worsens beyond -$110 million in FY25 or FY26	Net income: $7.444M FY2026-Q2; GAAP. Published target: Net loss less negative than -$95 million in FY25, improving in FY26. Target period is not explicitly aligned with this observation. Source published Aug 10, 20267,444,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: c7277963-c6e1-439c-9966-145505ddab21. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain listing compliance and avoid delisting	A supporting condition in P3 Health Partners Inc's published investment case. The stated target is No delisting notices or continued listing rule failures.	Under Pressure	Receipt of new delisting notices or failure to meet listing standards	Delisting notice received Nasdaq delisting notices filed May 2026; no evidence of compliance restoration. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Increase revenue to $1.5B-$1.7B in 2026	A primary condition in P3 Health Partners Inc's published investment case. The stated target is >= $1.5 billion and <= $1.7 billion total revenue.	Intact	Total revenue falls below $1.4 billion in FY26	Revenue: $386.381M FY2026-Q2; GAAP. Published target: >= $1.5 billion and <= $1.7 billion total revenue. Target period is not explicitly aligned with this observation. Source published Aug 10, 2026386,381,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: c7277963-c6e1-439c-9966-145505ddab21. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Revenue grew modestly from $373.2M in 2025-Q1 to $386.4M in 2026-Q1. Management raised full-year 2026 revenue guidance from $1.5B-$1.7B at 2025-Q4 to $1.5B-$1.6B at 2026-Q2. The trajectory shows steady revenue growth and consistent guidance updates aligned with this priority. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	2 / 2
2026-07-25	Unavailable	Unavailable	2 / 2
2026-07-26	Unavailable	Unavailable	2 / 2
2026-07-27	Unavailable	Unavailable	2 / 2
2026-07-28	Unavailable	Unavailable	2 / 2
2026-07-29	Unavailable	Unavailable	2 / 2
2026-07-30	Unavailable	Unavailable	2 / 2
2026-07-31	Unavailable	Unavailable	2 / 2
2026-08-01	Unavailable	Unavailable	2 / 2
2026-08-02	Unavailable	Unavailable	2 / 2
2026-08-03	Unavailable	Unavailable	2 / 2
2026-08-04	Unavailable	Unavailable	2 / 2
2026-08-05	Unavailable	Unavailable	2 / 2
2026-08-06	Unavailable	Unavailable	2 / 2
2026-08-07	Unavailable	Unavailable	2 / 2
2026-08-08	Unavailable	Unavailable	2 / 2
2026-08-09	Unavailable	Unavailable	2 / 2
2026-08-10	Unavailable	Unavailable	2 / 2
2026-08-12	Unavailable	Unavailable	2 / 2
2026-08-13	Unavailable	Unavailable	2 / 2
2026-08-14	Unavailable	Unavailable	2 / 2
2026-08-15	Unavailable	Unavailable	2 / 2
2026-08-16	Unavailable	Unavailable	2 / 2
2026-08-17	Unavailable	Unavailable	2 / 2
2026-08-18	Unavailable	Unavailable	2 / 2
2026-08-19	Unavailable	Unavailable	2 / 2
2026-08-20	Unavailable	Unavailable	2 / 2
2026-08-21	Unavailable	Unavailable	2 / 2
2026-08-22	Unavailable	Unavailable	2 / 2
2026-08-23	Unavailable	Unavailable	2 / 2
2026-08-24	Unavailable	Unavailable	2 / 2
2026-08-25	Unavailable	Unavailable	2 / 2
2026-08-26	Unavailable	Unavailable	2 / 2
2026-08-27	Unavailable	Unavailable	2 / 2
2026-08-28	Unavailable	Unavailable	2 / 2
2026-08-29	Unavailable	Unavailable	1 / 2
2026-08-30	Unavailable	Unavailable	1 / 2
2026-08-31	Unavailable	Unavailable	1 / 2
2026-09-01	Unavailable	Unavailable	1 / 2
2026-09-02	Unavailable	Unavailable	1 / 2
2026-09-03	Unavailable	Unavailable	1 / 2
2026-09-04	Unavailable	Unavailable	1 / 2
2026-09-05	Unavailable	Unavailable	1 / 2
2026-09-06	Unavailable	Unavailable	1 / 2
2026-09-07	Unavailable	Unavailable	1 / 2
2026-09-08	Unavailable	Unavailable	1 / 2
2026-09-09	Unavailable	Unavailable	1 / 2
2026-09-10	Unavailable	Unavailable	1 / 2
2026-09-11	Unavailable	Unavailable	1 / 2
2026-09-12	Unavailable	Unavailable	1 / 2
2026-09-13	Unavailable	Unavailable	1 / 2
2026-09-14	Unavailable	Unavailable	1 / 2
2026-09-15	Unavailable	Unavailable	1 / 2
2026-09-16	Unavailable	Unavailable	1 / 2
2026-09-17	Unavailable	Unavailable	1 / 2
2026-09-18	Unavailable	Unavailable	1 / 2
2026-09-19	Unavailable	Unavailable	1 / 2
2026-09-20	Unavailable	Unavailable	1 / 2
2026-09-21	Unavailable	Unavailable	1 / 2
2026-09-22	Unavailable	Unavailable	1 / 2
2026-09-23	Unavailable	Unavailable	1 / 2
2026-09-24	Unavailable	Unavailable	1 / 2
2026-09-25	Unavailable	Unavailable	1 / 2
2026-09-26	Unavailable	Unavailable	1 / 2
2026-09-27	Unavailable	Unavailable	1 / 2
2026-09-28	Unavailable	Unavailable	1 / 2
2026-09-29	Unavailable	Unavailable	1 / 2
2026-09-30	Unavailable	Unavailable	1 / 2
2026-10-01	Unavailable	Unavailable	1 / 2
2026-10-02	Unavailable	Unavailable	1 / 2
2026-10-03	Unavailable	Unavailable	1 / 2
2026-10-04	Unavailable	Unavailable	1 / 2
2026-10-05	Unavailable	Unavailable	1 / 2
2026-10-06	Unavailable	Unavailable	1 / 2
2026-10-07	Unavailable	Unavailable	1 / 2
2026-10-08	Unavailable	Unavailable	1 / 2
2026-10-09	Unavailable	Unavailable	1 / 2
2026-10-10	Unavailable	Unavailable	1 / 2
2026-10-11	Unavailable	Unavailable	1 / 2
2026-10-12	Unavailable	Unavailable	1 / 2
2026-10-13	Unavailable	Unavailable	1 / 2
2026-10-14	Unavailable	Unavailable	1 / 2
2026-10-15	Unavailable	Unavailable	1 / 2
2026-10-16	Unavailable	Unavailable	1 / 2
2026-10-17	Unavailable	Unavailable	1 / 2
2026-10-18	Unavailable	Unavailable	1 / 2
2026-10-19	Unavailable	Unavailable	1 / 2
2026-10-20	Unavailable	Unavailable	1 / 2
2026-10-21	Unavailable	Unavailable	1 / 2
2026-10-22	Unavailable	Unavailable	1 / 2
2026-10-23	Unavailable	Unavailable	1 / 2
2026-10-24	Unavailable	Unavailable	1 / 2

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	1	1
2026-06-01	1	1
2026-07-01	1	1
2026-08-01	1	1
2026-09-01	1	1
2026-10-01	1	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 1 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Raise adjusted EBITDA to $40M in 2026Direct metric needs a verified mapping
Reduce net losses toward break-evenNet income: $7.444M
Maintain listing compliance and avoid delistingPublished status: Under Pressure
Increase revenue to $1.5B-$1.7B in 2026Revenue: $386.381M

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.5%Typical daily move · historical

Downside history

-82.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

P3 Health Partners Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

PIII is a high-risk, loss-making business with recent financial performance described as strong and a Healthcare sector tailwind. The long-term thesis remains intact, but its signal has shifted from mildly favorable to mixed, and management execution has been volatile.

What's priced into P3 Health Partners Inc

The evidence does not provide a peer valuation comparison or a clear account of what expectations the market already assumes. Its valuation measure fell from 70.0 to 55.6, a 14.4-point decline, but that alone does not establish whether the shares are cheap, fair, or expensive.

What the fundamentals likely do

Revenue rose modestly from $373.2 million in 2025-Q1 to $386.4 million in 2026-Q1, and adjusted EBITDA improved from a loss to a gain by 2026-Q2. Management raised its 2026 adjusted EBITDA outlook to a $40 million midpoint after Q1 and Q2 results, while its revenue outlook narrowed to $1.5 billion to $1.6 billion; Nasdaq listing compliance remains an issue. Near-term results are hard to assess, with erratic earnings surprises and a 41% estimated miss probability in the evidence.

What P3 Health Partners Inc hinges on